ACI — Albertsons Companies, Inc.

Summary of ACI Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 Adjusted EBITDA: $903 million, better than expected, including $68 million from a 53rd week.
• Q4 Adjusted EPS: $0.48 per diluted share.
• Identical Sales Growth: Increased by 0.7%, impacted by approximately 145 basis points from pharmacy-related headwinds, primarily due to the Inflation Reduction Act (IRA).
• Full Year Adjusted EBITDA: $3.9 billion, with identical sales growth of 2%.
• Gross Margin: 27.2% in Q4, a decline of 25 basis points year-over-year, influenced by a shift towards digital sales and IRA impacts.
• Capital Returns: Over $1.8 billion returned to shareholders through dividends and share repurchases.

2. Strategic Updates and Business Highlights

• Dividend Increase: Announced a 13% increase in quarterly dividend to $0.68 per share and refreshed share repurchase authorization to $2 billion.
• Strategic Focus: Emphasizing personalization in grocery shopping, leveraging AI and technology to enhance customer experience and operational efficiency.
• Digital Growth: Digital sales penetration surpassed 10%, with a 16% growth in digital sales, primarily driven by first-party offerings.
• Loyalty Program: Membership grew by 12% to over 51 million, enhancing customer engagement and retention.
• Pharmacy Strategy: Focused on improving profitability despite headwinds from the IRA, with expectations for continued growth in pharmacy scripts.

3. Forward Guidance and Outlook

• 2026 Identical Sales Guidance: Expected to range from 0% to 1%, or 1.5% to 2.5% excluding IRA impacts, with a sequential improvement anticipated throughout the year.
• Adjusted EBITDA for 2026: Projected between $3.85 billion and $3.925 billion, reflecting growth of approximately 2.5% at the top end.
• Capital Expenditures: Expected to be between $2 billion and $2.2 billion, focusing on store modernization and technology investments.
• Productivity Initiatives: A $2 billion productivity program over three years aimed at enhancing operational efficiency.

4. Bad News, Challenges, or Points of Concern

• Pharmacy Headwinds: Significant impact from the IRA, leading to a decline in pharmacy sales and pressure on overall identical sales.
• Market Pressures: Continued pressure on lower-income cohorts affecting unit sales, with expectations for a challenging first quarter of 2026.
• Gross Margin Concerns: Anticipated flat to slightly improved margins in 2026, with risks from rising fuel costs and competitive pricing pressures.
• Competitive Landscape: Increased competition in the grocery sector, necessitating surgical pricing strategies to maintain value perception.

5. Notable Q&A Insights

• Productivity Focus: Management emphasized the importance of productivity initiatives, with expectations for significant savings primarily from SG&A improvements.
• Digital Strategy: Strong growth in digital sales, with a focus on enhancing customer experience through AI and personalized offerings.
• Consumer Behavior: Noted a shift towards value among lower-income consumers, with increased cross-shopping trends impacting store traffic.
• GLP-1 Drug Impact: Continued moderation in GLP-1 growth expected to affect pharmacy traffic, but management believes core customers will remain loyal.
• CapEx and Store Investments: Plans for increased CapEx in 2026, with expectations for new store openings and remodels to drive future growth.

Overall, Albertsons demonstrated resilience in its financial performance despite facing significant headwinds, particularly in the pharmacy segment. The company's strategic focus on technology, personalization, and operational efficiency positions it for potential growth in the coming year, although challenges in consumer behavior and competitive pressures remain.